|
Market Closed -
NSE India S.E.
12:05:10 13/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 1,932.00 INR | -0.62% |
|
-0.41% | +12.35% |
| 08-05 | CRISIL Keeps AAA Rating on Sun Pharmaceutical's Bank Facilities | MT |
| 07-31 | Sun Pharmaceutical Industries Limited, Q1 2027 Earnings Call, Jul 31, 2026 |
| Market Cap | 4,636B 48.6B 42.11B 39.45B 35.99B 67.65B 68.69B 464B 181B 2,321B 182B 179B 7,740B | P/E 2027 * |
35.6x | P/E 2028 * | 30.2x |
|---|---|---|---|---|---|
| Enterprise Value | 4,356B 45.68B 39.57B 37.08B 33.82B 63.58B 64.56B 436B 170B 2,181B 171B 168B 7,274B | EV / Sales 2027 * |
6.69x | EV / Sales 2028 * | 5.88x |
| Free-Float |
44.39% | Yield 2027 * |
0.88% | Yield 2028 * | 1.03% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | -0.62% | ||
| 1 week | -0.41% | ||
| Current month | -2.94% | ||
| 1 month | -0.18% | ||
| 3 months | +4.68% | ||
| 6 months | +12.66% | ||
| Current year | +12.35% |
| 1 week | 1,925.1 |  | 1,965 |
| 1 month | 1,910 | | 2,046.9 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,548 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 31/08/2025 | |
| Director of Finance/CFO | 58 | 30/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 31/08/2025 | |
| Director/Board Member | 73 | 24/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.62% | -0.41% | +19.10% | +70.62% | 48.9B | |
| +1.51% | +5.34% | +57.99% | +122.57% | 40.42B | |
| -3.13% | +4.12% | +22.15% | +79.32% | 12.6B | |
| -0.29% | 0.00% | -4.13% | +16.69% | 12.39B | |
| -2.89% | -0.76% | +30.40% | +135.91% | 9.07B | |
| -1.77% | +5.96% | +22.02% | +37.63% | 7.53B | |
| +0.06% | +5.06% | +40.35% | -13.51% | 7.13B | |
| +1.31% | +2.70% | +12.72% | +189.51% | 6.78B | |
| +1.45% | +4.22% | -24.30% | +30.37% | 5.83B | |
| +2.08% | +5.15% | +34.01% | +109.43% | 4.64B | |
| Average | -0.23% | +2.79% | +21.03% | +77.85% | 15.53B | |
| Weighted average by Cap. | -0.16% | +2.39% | +27.93% | +83.73% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 651B 6.82B 5.91B 5.54B 5.05B 9.5B 9.65B 65.16B 25.47B 326B 25.62B 25.07B 1,087B | 729B 7.64B 6.62B 6.2B 5.66B 10.64B 10.8B 72.94B 28.51B 365B 28.69B 28.06B 1,217B |
| Net income | 130B 1.36B 1.18B 1.11B 1.01B 1.9B 1.93B 13.03B 5.09B 65.17B 5.12B 5.01B 217B | 154B 1.62B 1.4B 1.31B 1.2B 2.25B 2.28B 15.43B 6.03B 77.2B 6.07B 5.94B 257B |
| Net Debt | -279B -2.93B -2.53B -2.37B -2.17B -4.07B -4.14B -27.93B -10.92B -140B -10.98B -10.75B -466B | -349B -3.66B -3.17B -2.97B -2.71B -5.1B -5.17B -34.95B -13.66B -175B -13.75B -13.45B -583B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/08/26 | ₹1,932.00 | -0.62% | 1,216,049 |
| 12/08/26 | ₹1,944.00 | +0.10% | 1,536,383 |
| 11/08/26 | ₹1,942.00 | -0.12% | 2,125,972 |
| 10/08/26 | ₹1,944.40 | -0.03% | 1,726,946 |
| 07/08/26 | ₹1,945.00 | -0.31% | 2,425,268 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
